amiodarone has been researched along with atorvastatin in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Bruggisser, M; Franz, CC; Krähenbühl, S; Rätz Bravo, AE | 1 |
| El-Mohandes, EM; Hassan, YF; Khalaf, HA; Moustafa, AM | 1 |
| Baylon, JL; Denisov, IG; Grinkova, YV; Sligar, SG; Tajkhorshid, E | 1 |
| Duzgun, Z; Eroglu, Z | 1 |
| Fujibuchi, W; Kobayashi, K; Panina, Y; Sone, H; Yamane, J | 1 |
| Li, Z; Tu, Y; Zhang, J; Zhang, M; Zhou, Q; Zong, W | 1 |
| Ainsworth, M; Bookstaver, D; Gleaton, M; Milner, E | 1 |
| Bando, Y; Ishii, H; Otori, K; Yokota, N | 1 |
1 review(s) available for amiodarone and atorvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
15 other study(ies) available for amiodarone and atorvastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Adverse events with concomitant amiodarone and statin therapy.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Amiodarone; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Simvastatin; United States; United States Food and Drug Administration | 2005 |
[Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Coronary Artery Bypass, Off-Pump; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Fluconazole; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Postoperative Complications; Pyrroles; Rhabdomyolysis | 2011 |
The role of mast cells and macrophages in amiodarone induced pulmonary fibrosis and the possible attenuating role of atorvastatin.
Topics: Amiodarone; Animals; Atorvastatin; Immunohistochemistry; Macrophages; Male; Mast Cells; Pulmonary Fibrosis; Rats; Reference Standards; Staining and Labeling | 2017 |
Drug-Drug Interactions between Atorvastatin and Dronedarone Mediated by Monomeric CYP3A4.
Topics: Allosteric Regulation; Allosteric Site; Amiodarone; Animals; Atorvastatin; Binding Sites; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Dronedarone; Drug Interactions; Humans; Kinetics; Models, Molecular; Molecular Dynamics Simulation; NADPH-Ferrihemoprotein Reductase; Protein Binding; Protein Conformation; Rats | 2018 |
Role of cardiac drugs and flavonoids on the IRE1-JNK pathway as revealed by re-ranked molecular docking scores, MM/PBSA and umbrella sampling.
Topics: Amiodarone; Atorvastatin; Endoplasmic Reticulum Stress; Flavonoids; MAP Kinase Signaling System; Molecular Docking Simulation; Protein Serine-Threonine Kinases | 2022 |
Human ES and iPS cells display less drug resistance than differentiated cells, and naïve-state induction further decreases drug resistance.
Topics: Amiodarone; Animals; Aspirin; Atorvastatin; Cell Differentiation; Cell Line; Clotrimazole; Drug Resistance; Drug Resistance, Multiple; Embryonic Stem Cells; Humans; Induced Pluripotent Stem Cells | 2021 |
Effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI).
Topics: Amiodarone; Atorvastatin; Cardiovascular Agents; Case-Control Studies; China; Creatine Kinase, MB Form; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Random Allocation; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2021 |
Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
Topics: Adult; Aged; Amiodarone; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrazoles; Pyridones; Rosuvastatin Calcium; Simvastatin | 2022 |
[Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir].
Topics: Adenosine Monophosphate; Alanine; Amiodarone; Anticoagulants; Atorvastatin; Bisoprolol; COVID-19 Drug Treatment; Dexamethasone; Diltiazem; Drug Interactions; Humans; International Normalized Ratio; Male; Middle Aged; Warfarin | 2022 |